Rosuvastatin protects against podocyte apoptosis in vitro
about
Mediators and mechanisms of heat shock protein 70 based cytoprotection in obstructive nephropathyWt-1 Expression Linked to Nitric Oxide Availability during Neonatal Obstructive NephropathyCDK inhibitor p21 is prosurvival in adriamycin-induced podocyte injury, in vitro and in vivo.Simvastatin protects bladder and renal functions following spinal cord injury in rats.Dietary supplementation with essential amino acids boosts the beneficial effects of rosuvastatin on mouse kidneyMarker expression, behaviors, and responses vary in different lines of conditionally immortalized cultured podocytes.Involvement of Rho-associated protein kinase (ROCK) and bone morphogenetic protein-binding endothelial cell precursor-derived regulator (BMPER) in high glucose-increased alkaline phosphatase expression and activity in human coronary artery smooth muScope and mechanisms of obesity-related renal disease.Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.Anaplastic lymphoma kinase: activating mechanisms and signaling pathways.Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?The lipid story in chronic kidney disease: a long story with a happy end?Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.Simvastatin ameliorates renal lipidosis through the suppression of renal CXCL16 expression in mice with adriamycin-induced nephropathy.Apoptosis occurs differentially according to glomerular size in diabetic kidney disease.
P2860
Q26801311-809DF12E-7D62-44D0-8B99-A26F8B22FDA5Q26851512-CBB182A7-B6F2-4EE6-9CBA-968C3B20C3B1Q33529367-2705DE98-9BBC-475F-808B-456E1555F78AQ33864425-AE25024B-2A34-4163-9DF4-25A53EF18B21Q34045750-9F6796A5-73B6-44B2-8DE4-36CE2B5E8A65Q35216791-8B86ADCD-AA74-430D-B9B6-73F15F4027D8Q35945951-B46FC17E-5D19-4EA2-9E85-60DDCD12BCC1Q37687825-3603E76B-C5D8-41EB-A31C-5D4DDAC24B33Q37904098-5E72EB66-DE94-423D-9308-A3C670D935F3Q37971668-DDB421AE-C27A-4094-BDCB-242ACFD7DBFFQ38458152-5825DEE0-7FF2-49DF-B27E-C7C062D6C81EQ42912193-2E06926E-549C-4464-AF45-4B49A5656F23Q42933669-7EB7712A-DF4A-4F50-96F6-86F8FD54A3F8Q43064999-4AFBE826-C3CD-437F-811E-DA9310D962DCQ47372589-596A1300-A653-412A-B572-C7F87DFCD547
P2860
Rosuvastatin protects against podocyte apoptosis in vitro
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Rosuvastatin protects against podocyte apoptosis in vitro
@ast
Rosuvastatin protects against podocyte apoptosis in vitro
@en
type
label
Rosuvastatin protects against podocyte apoptosis in vitro
@ast
Rosuvastatin protects against podocyte apoptosis in vitro
@en
prefLabel
Rosuvastatin protects against podocyte apoptosis in vitro
@ast
Rosuvastatin protects against podocyte apoptosis in vitro
@en
P2093
P2860
P356
P1476
Rosuvastatin protects against podocyte apoptosis in vitro
@en
P2093
Fionnuala C Cormack-Aboud
Jeffrey W Pippin
Paul T Brinkkoetter
Raghu V Durvasula
Stuart J Shankland
P2860
P304
P356
10.1093/NDT/GFN528
P407
P577
2008-09-27T00:00:00Z